Madison Skin & Research, Inc.   Report issue

For profit Phase 3
Founded: Madison WI United States (2000)

Organization Overview

First Clinical Trial
2011
NCT01318733
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

brimonidine (alphagan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Erythema (Phase 3)

Rosacea (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1